O
AXSM icon

OrbiMed’s Axsome Therapeutics AXSM Stock Holding History

OrbiMed’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$2.83M – 162
2021
Q1 		$2.83M Buy
+50,000
New +$3.52M 0.03% 149

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed's AXSM Position: Q1 2026 in Review

OrbiMed reduced its Axsome Therapeutics (AXSM) stake by 15% in Q1 2026, selling an estimated $6.77M and leaving 213,921 shares worth $36.2M. The position accounts for 0.72% of the portfolio, ranked #42.

OrbiMed first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. The position peaked at $64.6M in Q3 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • OrbiMed held 213,921 shares of Axsome Therapeutics worth $36.2M as of Q1 2026.
  • OrbiMed sold 39,200 Axsome Therapeutics shares in Q1 2026, an estimated $6.77M.
  • Axsome Therapeutics made up 0.72% of OrbiMed's portfolio in Q1 2026, its #42 holding.
  • OrbiMed first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • OrbiMed's Axsome Therapeutics position peaked at $64.6M in Q3 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.